We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Becton Dickinson and Company | NYSE:BDX | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 236.58 | 6 | 13:18:05 |
By Kimberly Chin
The U.S. Food and Drug Administration has granted emergency-use authorization to Becton Dickinson & Co. for its Covid-19 point-of-care antigen test, the second such test to get authorization under the program, the health regulator said.
The test can be used on Becton's Veritor Plus System, a device that provides test results in less than 15 minutes and is targeted for healthcare providers, lab workers in physician offices and others in the health sector, the company said early Monday.
"Expanding America's testing capabilities is the result of partnership and ingenuity between the federal government, private sector and academia. Today's authorization is another achievement of that work," said FDA Commissioner Stephen Hahn.
An antigen test looks for the disease itself, as opposed to antibody tests that look for traces of past exposure.
In May, the agency granted emergency-use authorization to Quidel Corp. for the first antigen test for the Covid-19 virus.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
July 06, 2020 15:05 ET (19:05 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Becton Dickinson Chart |
1 Month Becton Dickinson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions